"I'm brutally pragmatic. I want to figure out what is absolutely the cleanest and fastest path. The thing the team has heard repeatedly is KISS — keep it simple, stupid."
Srinivas Rao grew up in Clarksburg, Kentucky, planned to major in physics at Yale, switched to computer engineering, then did a master's in digital signal processing, then an MD-PhD in pharmacology. What looks like a circuitous path has a clean through line: every turn was toward application. Not pure research for its own sake — how do you actually solve the problem?
That instinct has defined his career at atai Life Sciences. He joined in April 2019 as Chief Scientific Officer, helped transform the company from a family-office investment vehicle into an operating biopharmaceutical platform, and now serves as Co-CEO alongside co-founder Florian Brand. The portfolio he has built reflects his engineering disposition: an oral thin film DMT compound designed to slot into the infrastructure Spravato already built, an MDMA enantiomer with unexpected psychedelic-like properties that opened a path to social anxiety disorder, and RL-007 for cognitive impairment in schizophrenia — a compound he backed in part because the indication is so hard that most companies shy away from it.
This conversation moves through the full atai story: how the company evolved from fund to operating company, how engineering principles shape drug delivery decisions, what the results from the R-MDMA program revealed that nobody expected, why Srini thinks the interplay between neuroplasticity and network disruption is the key question in psychedelic medicine, and what he has learned about building a focused portfolio in a space that is perpetually tempting you to add more.
The Engineering Mindset: Why KISS Changes How You Build a Biotech
Srini's central organizing principle is simplicity — not as an aesthetic preference but as a survival strategy. Drug development is already hard. Every additional degree of complexity compounds the ways things can go wrong. When you are formulating a delivery mechanism, designing a trial, or building a portfolio, the right question is not "what's the most sophisticated approach?" It's "what's the cleanest and fastest path?"
This shows up most visibly in how atai approached their DMT program. They could have gone with injectable delivery. Injectables are relatively easy to manufacture. Instead they chose oral thin films — a sublingual dissolving strip — knowing it would be harder to formulate and manufacture but far better for scalability, patient acceptance, and commercial adoption. The bet paid off: their pharmacokinetic results exceeded expectations, delivering more drug than anticipated.
The same logic drove the decision to target a two-hour duration window for the treatment experience. Spravato (esketamine) had already done the heavy lifting of establishing a clinical infrastructure for supervised psychedelic-adjacent treatments — 4,500 clinic sites, regulatory pathways cleared, prescribers trained. A drug that fits the same duration window gets to ride that infrastructure rather than build from scratch. That's not a compromise. That's pragmatism.
From Fund to Operating Company: How atai Built Its Platform
atai started, as Srini describes it, more like a family office or fund than an operating company. The first investment was in Compass Pathways. The second was a company called PERCEPTION, co-founded by Jay Kranzler — Srini's first boss in the industry. When Kranzler reached out about potentially being CEO of PERCEPTION, Srini met the broader atai team and concluded it made more sense to join at the atai level, given the ambition to build a real operating company.
The model that evolved: take early-stage academic companies — often one or two people, deep scientific expertise but no capacity to run a clinical program — and provide the infrastructure they need without displacing the founders. Pull in formulation expertise, manufacturing, clinical operations, regulatory. Leave the people who know the asset best inside the ecosystem, but give them what they need to move.
That model allowed atai to build a portfolio across multiple compounds and indications without having to stand up a full company behind each one from scratch. Over time, portfolio rationalization has narrowed the scope — not by design so much as by outcome. Programs that didn't work were cut. The ones that did were resourced. The result is a tighter portfolio with compounds that Srini believes are genuinely differentiated.
DMT as an Oral Thin Film: Engineering the Delivery
The DMT asset story illustrates how pragmatic constraints shaped an innovative decision. The core hypothesis was to design something that fits into the existing Spravato paradigm: two-hour treatment window, supervised clinic administration, no overnight stay. That constraint came first. Delivery mechanism was downstream of it.
Injectable would have been simpler to manufacture. But the scalability and patient experience considerations pushed toward something more like a tablet or film. Oral thin films — sublingual dissolving strips — are niche but proven in other categories. atai found a group that could do it, knew it would be hard, and went after it.
The pharmacokinetic results came in better than anticipated. The film delivered drug at levels and consistency that exceeded the pre-formulation models. That kind of outcome — where the hard thing works better than expected — validates the approach. It also sets up the competitive position: anyone trying to replicate it now faces the same formulation challenge atai has already solved.
Srini's decision to avoid inhaled routes was deliberate and informed by direct experience. At a previous company he worked with an inhaled atypical antipsychotic — the FDA loaded that approval with so many hurdles that the experience left a lasting impression. Anything going into the lungs triggers intense regulatory scrutiny. He wanted no part of it.
Treatment-Resistant Depression: Two Bets on One Space
A reasonable question about atai's portfolio: they have a stake in Beckley Psytech, which is developing 5-MeO-DMT, and they are also developing their own DMT compound — both targeting treatment-resistant depression. How is that not self-competition?
Srini's answer is pharmacological. DMT and 5-MeO-DMT are different molecules with meaningfully different receptor profiles. 5-MeO-DMT has strong activity at the 5-HT1A receptor that DMT lacks. Subjectively, subjects report different experiences. The clinical implication: they may work in different patient populations, or serve as rotation options for patients who don't respond to one versus the other — the same logic that supports having multiple SSRIs despite superficially similar mechanisms.
The more grounding framing is market size. There are roughly three million patients with treatment-resistant depression in the US. Current Spravato adoption is approximately 50,000 patients generating $1 billion in annual run rate. The gap between where the market is and where the science suggests it could go is enormous. The space is big enough for multiple compounds with different profiles to coexist and find their patient populations.
R-MDMA and Social Anxiety Disorder: An Unexpected Pivot
The R-MDMA program at atai started from a pharmacological hypothesis: MDMA is a racemic mixture of two mirror-image molecules (enantiomers). The S-enantiomer is primarily responsible for the stimulant, dopaminergic, norepinephrinergic properties — the abuse potential, the blood pressure spikes, the bruxism, the hyperthermia. The R-enantiomer is much more serotonergic. By isolating R-MDMA, you might preserve the therapeutic benefit while eliminating the safety liabilities.
The Phase 1 results confirmed the safety hypothesis. What nobody expected was how the subjective profile looked: much more like a classical psychedelic than racemic MDMA, on measures like the 5-Dimensional Altered States of Consciousness scale. The experience was inwardly focused. Subjects were quiet, internal, not trying to externalize — the opposite of what therapists see with racemic MDMA, where redirecting patients back inward is a constant intervention.
That observation, combined with dose-response data on the emotional breakthrough inventory (a measure that has been correlated with efficacy in psilocybin studies) and marked improvements in self-compassion scores, opened up a new indication: social anxiety disorder. Social anxiety is prevalent, deeply impactful, became more prominent post-COVID, and has had almost no therapeutic innovation in 20 years. The approved options — SSRIs and SNRIs from the early 2000s — are the same tools used for depression. Srini sees it as an indication where psilocybin-era tools were 10 years ago: a large unmet need, early interest, no recent approvals, and significant room for a new approach.
The Neuroplasticity Debate: Is the Experience the Medicine?
One of the most substantive exchanges in this conversation is about the mechanism of psychedelics — specifically whether the therapeutic benefit comes from the subjective experience (the neuroplastic activity, the insights, the emotional processing), from the network disruption itself, or from their interplay.
Srini's view: it's the interplay. Network disruption — the altered connectivity and perceptual distortions of the psychedelic state — creates a window of plasticity. That window is what therapy happens inside. The two phenomena coexist and amplify each other. Neither alone is sufficient.
He illustrates the concept through thought experiments. Cannabinoids also cause network disruption, and there are cannabis-like behavioral effects. But there is no marked release of growth factors, no persistent beneficial effect. Network disruption without plasticity just goes away. Conversely, profound neuroplasticity without structured context could be neutral or adverse — highly plastic states can deepen ruminative patterns just as easily as they can disrupt them. In a population of depressed patients with negative self-referential thought loops, inducing plasticity without the right context could actually reinforce pathology.
The non-hallucinogenic psychedelic question — whether you can get the therapeutic benefit without the subjective experience — is real and interesting. Delix Therapeutics is working on it, with Phase 2 data expected within a year or two of the recording. Srini is genuinely uncertain about the answer. His prior is that the interplay matters. The data will tell.
Clinical Context: Preparation and Integration Matter
On the question of therapy-assisted versus monitored psychedelic administration, Srini is pragmatic again. During the acute experience window, there is not much space for traditional therapy. What's happening is too intense and too inward. The role of the clinical staff is primarily safety monitoring — the same role played by clinical staff during esketamine treatment. Someone needs to be present, watching for adverse reactions, ready to intervene.
What matters before and after: preparation and integration. Preparation is about ensuring the subject knows what they're getting into, is in a stable baseline mental state, and has some skills for managing challenging moments — box breathing, grounding techniques. There is a suggestibility element to the experience, and patients who arrive scared or preoccupied with recent trauma may have more difficult sessions.
Integration is about psychological safety. Things can surface during these experiences — repressed memories, emotional material, unresolved conflicts. After the session, the clinical team's job is to scan for any concerns about psychological stability, and to help the patient process what came up in ways that are therapeutically useful. It is not traditional psychotherapy, but it requires trained clinicians who know what to watch for.
Cognitive Impairment in Schizophrenia: Doing the Hard Thing First
RL-007, atai's compound for cognitive impairment associated with schizophrenia, came into the portfolio because of the compound's unusual phenotypic characterization. Most drug candidates are pharmacologically characterized — you know which receptors they hit and work backward from the mechanism. RL-007 was put through extensive animal studies and showed pro-cognitive effects at low doses and analgesic effects at high doses, without touching the usual receptor suspects. Receptor panel work suggested a GABAergic mechanism. There were already three human studies at the time of acquisition showing pro-cognitive effects.
The indication is objectively difficult. Cognitive impairment is nearly universal in schizophrenia — 85% of patients are affected — and is a major driver of disability, institutionalization, and cost. But the subjectivity of cognitive endpoints, the complexity of the patient population, and the entrenched view that schizophrenia is "too hard" have kept most companies away.
Srini's response to why start there: that's exactly why. The need is enormous. And some aspects of RL-007's pharmacology connect to the underlying excitation-inhibition balance deficits seen in schizophrenia. The compound is either GABAergic or glutamatergic — the same two target classes driving most current development in the space. Doing it first means the data will establish baselines for the indication, and success there potentially opens doors to broader cognitive impairment applications in dementias where the unmet need is equally massive.
Portfolio Construction: Focused Without Being Static
atai's portfolio has gotten leaner over time. The organic process of cutting programs that failed and not replacing them — combined with a deliberate push to KISS — has resulted in what Srini describes as a good place to be: DMT/VS-101 for treatment-resistant depression, R-MDMA/EMP-01 for social anxiety disorder, Ibogaine for opioid use disorder, and RL-007 for cognitive impairment in schizophrenia.
Each is differentiated. DMT and R-MDMA are pharmacologically distinct from the rest of the psychedelic field. Ibogaine targets substance use via a mechanism unlike anything else in psychiatry. RL-007 is in a completely different therapeutic area. The commercial logic is also additive: psychedelic-assisted treatments require specialist clinic infrastructure, and a company with multiple approved compounds can share that commercial infrastructure efficiently — the same small Salesforce reaching the same 4,500 Spravato-style clinics across multiple products.
The temptation to add programs is real. Srini describes himself as someone who genuinely loves the creative element — the blue-sky thinking, the new ideas, the early science. But finite resources, finite headcount, and the imperative to get these Phase 2 readouts done cleanly and quickly means the discipline of not replacing matters as much as the discipline of cutting.
What You'll Learn
- How an engineering background changes the way you approach drug delivery decisions
- Why atai chose oral thin film for DMT over simpler injectable administration
- How the FDA's history with inhaled drug products informed atai's route-of-administration choices
- Why two competing compounds (DMT and 5-MeO-DMT) in the same indication make sense commercially and clinically
- What R-MDMA's Phase 1 results revealed that changed the company's development strategy
- How network disruption and neuroplasticity interact in the psychedelic experience — and why both may be necessary
- Why cognitive impairment in schizophrenia is an underinvested indication despite enormous unmet need
- How a focused portfolio enables commercial synergies in the supervised clinic model
- What good preparation and integration look like in psychedelic clinical trials
Episode Highlights
- [00:18] Career Background: Engineering, Neuropharmacology, and How the Path Came Together
- [02:18] Starting atai: From Fund to Full Operating Company
- [05:22] The Engineering Mindset in Drug Development
- [06:59] DMT Oral Thin Film: Why Simplicity and Scalability Drove the Delivery Decision
- [10:23] Fitting Into the Spravato Infrastructure: The Two-Hour Treatment Window
- [13:00] DMT vs. 5-MeO-DMT: Competition or Complementary Bets?
- [16:05] R-MDMA: Separating the Two Enantiomers and What Happened Next
- [19:50] Neuroplasticity vs. Network Disruption: The Key Mechanistic Question
- [22:45] R-MDMA and Social Anxiety Disorder: An Unexpected Program
- [31:16] Trial Design, Preparation, and Integration in Psychedelic Clinical Trials
- [37:14] RL-007: Cognitive Impairment in Schizophrenia — Why Do the Hard Thing First
- [42:26] Portfolio Construction: The Value of Focused Compounds
- [47:00] Transition to CEO and the Future of atai
